TORONTO, ONTARIO--(Marketwire - June 13, 2012) - Cynapsus Therapeutics (CTH.V) today announced that an article discussing its APL-130277 drug candidate will be published in the July 2012 Issue of the Journal of Commercial Biotechnology. The article titled "Creating systemic oral transmucosal drug delivery strategies: Case study of APL-130277" was co-authored by Anthony Giovinazzo, President and CEO of Cynapsus, Nathan Bryson, Chief Scientific Officer of Cynapsus, and Timothy Tankosic, Managing Director of Aqua Partners, LLC.

The July 2012 issue of the Journal of Commercial Biotechnology will be published on July 1, 2012 and distributed earlier at the BIO International Convention (http://convention.bio.org/) being held in Boston, MA, USA, from June 18 to 21, 2012.

The article broadly addresses the strategic application of systemic oral transmucosal (i.e., sublingual and buccal) drug delivery. The article also provides a specific discussion of the scientific, clinical and commercial considerations driving APL-130277, an easy-to-administer, fast-acting, oral reformulation of an approved drug, apomorphine, being developed to rescue Parkinson's patients from "off" episodes. The principal advantages the oral transmucosal route and APL-130277 include: circumvention of first-pass hepatic metabolism in the gut, rapid onset of action, easy access via the oral cavity, easy administration for patients with dysphagia, and a high level of patient acceptance.

The full text version of the article is available at http://commercialbiotechnology.com (Subscription Required), or by contacting Anthony Giovinazzo at ajg@cynapsus.ca.

About Cynapsus Therapeutics

Cynapsus is a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease. Over one million people in the United States and an estimated 5 million people globally suffer from Parkinson's disease. Parkinson's disease is a chronic and progressive neurodegenerative disease that impacts motor activity, and its prevalence is increasing with the aging of the population. It is estimated that between 25 percent and 50 percent of patients experience off episodes in which they have impaired movement or speaking capabilities. Current medications only control the disease's symptoms, and most drugs become less effective over time as the disease progresses.

Cynapsus' lead drug candidate, APL-130277, is an easy-to-administer, fast-acting, oral reformulation of an approved drug, apomorphine, used to rescue patients from off episodes. Cynapsus is focused on rapidly maximizing the value of APL-130277 by completing pivotal studies in advance of a New Drug Application expected to be submitted in 2014. Cynapsus anticipates out-licensing to an appropriate pharmaceutical partner before such an application is submitted.

More information about Cynapsus (CTH.V) is available at http://www.cynapsus.ca and at the System for Electronic Document Analysis and Retrieval (SEDAR) at http://www.sedar.com.

About The Journal of Commercial Biotechnology

The Journal of Commercial Biotechnology is the definitive international quarterly publication for bioscience business professionals. The Journal is designed specifically for those professionals who need to enhance their knowledge of biotechnology business strategy and management, improve and advance their product development or want to keep up-to-date with current issues and industry trends. Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as Management, Policy, Finance, Law, Regulation and Bioethics.

See the article here:
Cynapsus Therapeutics has Article Published in Journal of Commercial Biotechnology